(Finance) – The pharmaceutical company Pfizer signed an agreement with the investment company Flagship Pioneering to invest 100 million dollars on the development of 10 new investigational drugs to treat diseases with few or no treatment options.
Flagship will invest 50 million dollars in partnership with Pfizer, which would secure access to Pioneering’s research platform and resources for preclinical studies, as well as granting drug development and a purchase option. The support of
Flagship and its platform member companies will be eligible to receive up to $700 million in rewards and royalties for each successfully commercialized program.